Natixis Advisors L.P. decreased its position in Qiagen NV (NYSE:QGEN) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,229 shares of the company’s stock after selling 1,479 shares during the period. Natixis Advisors L.P.’s holdings in Qiagen were worth $1,351,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. Lindbrook Capital LLC acquired a new position in shares of Qiagen in the fourth quarter valued at approximately $25,000. Bremer Trust National Association acquired a new position in shares of Qiagen in the fourth quarter valued at approximately $45,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Qiagen in the fourth quarter valued at approximately $118,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Qiagen by 38.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,528 shares of the company’s stock valued at $119,000 after buying an additional 976 shares during the last quarter. Finally, First Bank & Trust raised its position in shares of Qiagen by 12.7% in the fourth quarter. First Bank & Trust now owns 5,552 shares of the company’s stock valued at $191,000 after buying an additional 624 shares during the last quarter. 64.77% of the stock is currently owned by institutional investors and hedge funds.
Qiagen stock opened at $39.42 on Monday. The stock has a market cap of $8.89 billion, a PE ratio of 29.42, a PEG ratio of 2.23 and a beta of 0.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.22 and a quick ratio of 2.05. Qiagen NV has a one year low of $31.10 and a one year high of $40.42.
A number of equities research analysts recently issued reports on QGEN shares. Jefferies Financial Group restated a “neutral” rating on shares of Qiagen in a report on Monday, January 14th. Deutsche Bank restated a “buy” rating on shares of Qiagen in a report on Tuesday, January 29th. Finally, UBS Group assumed coverage on shares of Qiagen in a report on Friday, March 15th. They issued a “neutral” rating and a $42.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $41.17.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Story: Roth IRA
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.